UGCG and nasopharyngeal carcinoma: In this work, we selected glucosylceramide synthase EC 2.4.1.80 (GCS) as the possible target, as it is inhibited by Miglustat, a drug approved for the treatment of Gaucher disease [36,37] and NPC in patients with mild to moderate neurological symptoms.